CRISM THERAPEUTICS CORPORATION (CRTX) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the CRISM THERAPEUTICS CORPORATION investor presentation. Throughout this recorded meeting, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the q and a tab situated on the right hand corner of your screen. Just click q and a, type your question, question, press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted and publish responses where appropriate to do so. Before we begin, we'd like to submit the following poll. I'd now like to hand you over to Andrew Reb, CEO. Good afternoon, sir. So good afternoon. Thank you for taking the time to join this call to update you on our half year results for CRISM THERAPEUTICS CORPORATION. It's a privilege to present our progress since our vision to aim earlier this year. For those of you who don't know us, CRISM THERAPEUTICS, we're a drug delivery technology company, and our primary technology is localized treatments through chemotherapy of solid tumors effectively in the cancer indication. Following Honesty on AIM, clear priority was to bring on a new board for the for the company. And the my role here going forward is is chief executive of the company. Just to review my background, I'm a career in health care. I started off as a bench scientist many moons ago with GlaxoSmithKline, moved from a bench bench scientist due to commercial with what is now GE Healthcare, and which was really my business took on my work very much on the commercial side and sales, business development and licensing. My first startup was clinical DXS in Manchester, but joined the founders back in 2009, and we successfully exited to I've been involved in really, my ...